Clinical Perspectives of Lithium’s Neuroprotective Effect

Abstract

Evidence for a neuroprotective effect of lithium has accumulated over the last 2 decades, and this phenomenon has been regarded as an important mechanism of lithium action in mood disorders. It has been reflected by an increase in cerebral gray matter volume in lithium-treated subjects and by the favorable influence of lithium on cognitive functions. A neuroprotective effect of lithium also makes this ion a possible candidate for use as a therapeutic drug in neurology, especially in neurodegenerative disorders. In this paper, neurochemical mechanisms of neuroprotective action of lithium will be characterized. A possible association between the effect of lithium on brain structures reflected in neuroimaging studies, as well as on cognitive functions, and its neuroprotective action, will be considered. Data from experimental, epidemiological, and clinical studies have also pointed to an antidementia effect of lithium, bringing about some promise of using lithium in the treatment of mild cognitive impairment and Alzheimer’s disease. The results of attempts of employing lithium in other neurodegenerative disorders will also be discussed.

Key words

lithium - neuroprotection - Alzheimer’s disease

• References

• 1 Rybakowski JK. Lithium in neuropsychiatry. A 2010 update. World J Biol Psychiatry 2011; 12: 340-348
• 2 Quiroz JA, Machado-Vieira R, Zarate CA. et al. Novel insights into lithium’s mechanism of action: Neurotrophic and neuroprotective effects. Neuropsychobiology 2010; 62: 50-60
• 3 Rybakowski JK. BDNF gene: Functional Val66Met polymorphism in mood disorders and schizophrenia. Pharmacogenomics 2008; 9: 1589-1593
• 4 Rybakowski JK, Suwalska A, Skibinska M. et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 2005; 38: 166-170
• 5 Jope RS. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci 2011; 4: 16
• 6 Mendes CT, Mury FB, de Sa Moreira E. et al Lithium reduces Gsk3b mRNA levels: Implications for Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 2009; 259: 16-22
• 7 Leroy K, Ando K, Heraud C. et al. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J Alzheimers Dis. 2010; 19: 705-719
• 8 Sofola O, Kerr F, Rogers I. et al. Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer’s disease. PLoS Genet. 2010; 6: e1001087
• 9 Motoi Y, Shimada K, Ishiguro K. et al. Lithium and autophagy. ASC Chem Neurosci 2014; 5: 434-442
• 10 Baum AE, Akula N, Habanero M. et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry. 2008; 13: 197-207
• 11 Williams RS, Cheng L, Mudge AW. et al. A common mechanism of action for three mood-stabilizing drugs. Nature 2002; 417: 292-295
• 12 Willmroth F, Drieling T, Lamla U. et al. Sodium-myo-inositol co-transporter (SMIT-1) mRNA is increased in neutrophils of patients with bipolar 1 disorder and down-regulated under treatment with mood stabilizers. Int J Neuropsychopharmacol. 2007; 10: 63-71
• 13 Yildiz A, Guleryuz S, Ankerst DP. et al. Protein kinase C inhibition in the treatment of mania: A double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry. 2008; 65: 255-263
• 14 Machado-Vieira R, Pivovarova NB, Stanika RI. et al. The bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-triphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. Biol Psychiatry. 2011; 69: 344-352
• 15 Morris G, Berk M. The putative use of lithium in Alzheimer’s disease. Curr Alzheimer Res. 2016; 13: 853-861
• 16 Moore GJ, Bebchuk JM, Wilds IB. et al. Lithium-induced increase in human brain grey matter. Lancet 2000; 356: 1241-1242
• 17 Hajek T, Weiner MW. Neuroprotective effects of lithium in human brain? Food for thought. Curr Alzheimer Res. 2016; 13: 862-872
• 18 Hajek T, Bauer M, Simhandl C. et al. Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response. Psychol Med. 2014; 44: 507-517
• 19 Monkul ES, Matsuo K, Nicoletti MA. et al. Prefrontal gray matter increases in healthy individuals after lithium treatment: A voxel-based morphometry study. Neurosci Lett. 2007; 429: 7-11
• 20 Yucel K, Taylor VH, McKinnon MC. et al. Bilateral hippocampal volume increase in patients with bipolar disorder and short-term lithium treatment. Neuropsychopharmacology 2008; 13: 361-367
• 21 Moore GJ, Cortese BM, Glitz DA. et al. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry. 2009; 70: 699-705
• 22 Lyoo K, Dager SR, Kim JE. et al. Lithium-induced grey matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study. Neuropsychopharmacology 2010; 35: 1743-1750
• 23 Germana C, Kempton MJ, Sarnicola A. et al. The effects of lithium and anticonvulsants on brain structure in bipolar disorder. Acta Psychiatr Scand 2010; 122: 481-487
• 24 Berger GE, Wood SJ, Ross M. et al. Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. Curr Ther Des 2012; 15: 570-575
• 25 Yazlovitskaya EM, Edwards E, Thotala D. et al. Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation. Cancer Res. 2006; 66: 11179-11186
• 26 Nocjar C, Hammonds MD, Shim SS. Chronic lithium treatment magnifies learning in rats. Neuroscience 2007; 150: 774-788
• 27 Raust A, Daban C, Cochet B. et al. Neurocognitive performance as an endophenotype for bipolar disorder. Front Biosci. 2014; 6: 89-103
• 28 Rybakowski JK. Effect of lithium on neurocognitive functioning. Curr Alzheimer Res. 2016; 13: 887-893
• 29 Wingo AP, Wingo TS, Harvey PD. et al. Effect of lithium on cognitive performance: A meta-analysis. J Clin Psychiatry. 2009; 70: 1588-1597
• 30 Lopez-Jaramillo C, Lopera-Vasquez J, Ospina Duque J. et al. Lithium treatment effects on the neuropsychological functioning of patients with bipolar I disorder. J Clin Psychiatry. 2010; 71: 1055-1060
• 31 Rybakowski JK, Permoda-Osip A, Borkowska A. Response to prophylactic lithium in bipolar disorder may be associated with a preservation of executive cognitive functions. Eur Neuropsychopharmacol. 2009; 19: 791-795
• 32 Rybakowski JK, Suwalska A. Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol. 2010; 13: 617-622
• 33 Martinez-Aran A, Vieta E, Colom F. et al. Cognitive impairment in euthymic bipolar patients: Implications for clinical and functional outcome. Bipolar Disord. 2004; 6: 224-232
• 34 Dickerson FB, Boronow JJ, Stallings C. et al. Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder. Biol Psychiatry. 2004; 55: 588-593
• 35 Rybakowski JK, Amsterdam JD. Lithium prophylaxis and recurrent labial herpes infections. Lithium 1991; 2: 41-41
• 36 Schou M. Problems of lithium prophylaxis: Efficacy, serum lithium, selection of patients. Bibl Psychiatr. 1981; 160: 30-37
• 37 Donix M, Bauer M. Population studies of association between lithium and risk of neurodegenerative disorders. Curr Alzheimer Res. 2016; 13: 873-878
• 38 Kessing LV, Sondergard L, Forman JL. et al. Lithium treatment and the risk of dementia. Arch Gen Psychiatry. 2008; 65: 1331-1335
• 39 Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia?. Bipolar Disord 2010; 12: 97-94
• 40 Dunn N, Holmes C, Mullee M. Does lithium therapy protect against the onset of dementia?. Alzeimer Dis Assoc Disord 2005; 19: 20-22
• 41 Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer’s disease in elderly patients with bipolar disorder. Br J Psychiatry. 2007; 190: 359-360
• 42 Forlenza OV, Diniz BS, Radanovic M. et al. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomized controlled trials. Br J Psychiatry. 2011; 198: 351-356
• 43 Hampel H, Ewers M, Bürger K. et al. Lithium trial in Alzheimer’s disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009; 70: 922-931
• 44 Leyhe T, Eschweiler GW, Stransky E. et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer’s disease. J Alzheimers Dis. 2009; 16: 649-656
• 45 Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease. Curr Alzheimer Res. 2013; 10: 104-107
• 46 Kessing LV, Gerds TA, Knudsen NN. et al. Association of lithium in drinking water with the incidence of dementia. JAMA Psychiatry 2017; 74: 1005-1010
• 47 Matsunaga S, Kishi T, Annas P. et al. Lithium as a treatment for Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2015; 48: 403-410
• 48 Forlenza OV, Aprahamian I, de Paula VJ. et al. Lithium, a therapy for AD: current evidence from clinical trials of neurodegenerative disorders. Curr Alzheimer Res. 2016; 13: 879-886
• 49 Vestergaard P, Baastrup PC, Petersson H. Lithium treatment of Huntington’s chorea. A placebo-controlled clinical trial. Acta Psychiatr Scand. 1977; 56: 183-188
• 50 Senatorov VV, Ren M, Kanai H. et al. Short-term lithium treatment promotes neuronal survival and proliferation in rata striatum infused with quinolinic acid, an excitotoxic model of Huntington’s disease. Mol Psychiatry. 2004; 9: 371-385
• 51 Sarkar S, Krishna G, Imarisio S. et al. A rational mechanism for combination treatment of Huntington’s disease using lithium and rapamycin. Hum Mol Genet. 2008; 17: 170-178
• 52 Shin JH, Cho SI, Lim HR. et al. Concurrent administration of Neu2000 and lithium produces marked improvement of motor neuron survival, motor function, and mortality in a mouse model of amyotrophic lateral sclerosis. Mol Pharmacol. 2007; 71: 965-975
• 53 Fornai F, Longone P, Cafaro L. et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc NY Acad Sci 2008; 105: 2052-2057
• 54 Sacca F, Marsili A, Quarantelli M. et al. A randomized clinical trial of lithium in multiple system atrophy. J Neurol. 2013; 260: 458-461
• 55 Watase K, Gatchel JR, Sun Y. et al. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse. PLoS Med. 2007; 4: e182